Phesi’s SaaS predicts ‘what if’ and eases site selection costs, delays

By Maggie Lynch

- Last updated on GMT

(Image: Getty/TimeStopper)
(Image: Getty/TimeStopper)

Related tags SaaS Site selection clinical study Clinical trial AI

Phesi launches an AI-powered SaaS solution to mitigate potential costly delays through a search and select investigator function to determine trial sites for clinical studies.

The ClinSite tool launched by Phesi is a self-service, artificial intelligence (AI) powered Software as a Service (SaaS) solution, which  searches and selects investigator trial sites for biopharmaceutical companies using data collected by the clinical development analytics provider.

Phesi’s technology platform taps into data from 4.2 million physicians and 600,000 investigator sites identified from 80,000 sources and 330,000 clinical trials in 240 countries.

Jonathan Peachey, CEO of Phesi told us, “Our primary strategic goal is to partner with trial sponsors to remove barriers to conducting effective clinical trials, and to get novel therapies to patients faster​.”

“Smarter trials equal faster cures,”​ he added.

The intention behind the development of ClinSite is that it can be used directly by client teams under a SaaS, cloud-based license, “leaving Phesi to support the more difficult programs as a service, either directly or via formal alliance partners,”​ said Peachey.

According to the company, 250 clinical trials have used the solution to select investigator sites and those trials have enrolled patients 40% faster than other sites.

The solution uses an automated analytical approach and a proprietary data analytics platform, an approach, which Peachey said enables Phesi to conduct activities traditionally conducted in series and by different functional groups, simultaneously, by running ‘what if’ analyses’ in real time.

Peachey told us that the use of the service recently saved “millions of dollars by advising on the design of a gastroenterology protocol and determining the optimum number of sites requires and the best investigators.”​ The client estimated that it saved up to $5m by using the AI-based analysis.

The company expects to introduce an additional integrated module to optimize design of study protocols in 2020.

“We have seen a strong and growing demand for high quality, specialized providers in the niche we occupy, and we confidently expect dramatic further growth as the pharmaceutical industry faces increasing R&D productivity and cost pressures,”​ Peachey said.

Related news

Show more

Related products

show more

Drug Solubility and the Need for Speed

Drug Solubility and the Need for Speed

Lonza Small Molecules | 28-Mar-2023 | Technical / White Paper

A growing number of new chemical entities are highly insoluble, leading to problems with bioavailability. Drug manufacturers therefore have to find ways...

Are You Prepared to Meet the New FDA Guidelines?

Are You Prepared to Meet the New FDA Guidelines?

Elligo Health Research® | 23-Mar-2023 | Insight Guide

On April 15, 2022, the U.S. Food and Drug Administration issued a new draft guidance to clinical research sponsors on creating a plan to enroll more participants...

ODM and CDASH in CRF design

ODM and CDASH in CRF design

Formedix | 10-Mar-2023 | Technical / White Paper

The lesser-known Operational Data Model (ODM) standard is often overlooked as it's not required by any regulators. So, why should you be interested...

4 Warning Signs Your Research Site Is in Trouble

4 Warning Signs Your Research Site Is in Trouble

Elligo Health Research® | 10-Mar-2023 | Insight Guide

You want your clinical research practice to be a success for your business and your patients, but how can you tell if it’s in trouble? Read this article...

Related suppliers

Follow us

Products

View more

Webinars